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Anti-Vascular Endothelial Growth Factor Treatment in
Combination with Chemotherapy Delays Hematopoietic
Recovery Due to Decreased Proliferation of Bone Marrow
Hematopoietic Progenitor Cells
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Introduction: Targeting of cancer by chemotherapy in combination
with anti-vascular endothelial growth factor (VEGF) therapy has
demonstrated not only the clinical efficacy but also a higher risk of
serious hematologic complications including neutropenia. The pur-
pose of the study was to elucidate the molecular mechanisms
responsible for the development of neutropenia during the combi-
nation treatment.
Methods: Mouse model and in vitro studies were undertaken to
determine the effect of interference with VEGF signaling by VEGF-
specific agents or a multitargeted VEGF receptor (VEGFR) tyrosine
kinase inhibitor on proliferation of hematopoietic progenitor cell
(HPC) and repopulation of the hematopoietic compartment after
myeloablation.
Results: The studies demonstrated that blockage of VEGFR1 or
VEGFR2 signaling decreased HPC proliferation and impaired re-
population of the hematopoietic compartment after myelosuppres-
sion by slowing the progression of HPC through the cell cycle. The
combination of cytotoxic drugs and VEGFR tyrosine kinase inhib-
itor had an additive inhibitory effect and decreased proliferation of
HPC significantly stronger than either agent alone.
Conclusions: Signaling through both VEGFR1 and VEGFR2 is
required for normal reconstitution of the hematopoietic compart-
ment after cytotoxic chemotherapy.
Key Words: Neutropenia, Vascular endothelial growth factor, Che-
motherapy, Combination treatment, Hematopoietic progenitor cells.
(J Thorac Oncol. 2010;5: 1410–1415)
Targeting of cancer and its vasculature by combininganti-vascular endothelial growth factor (VEGF) therapy
and chemotherapy has drawn much interest because of its
improved clinical efficacy compared with chemotherapy
alone. Agents targeting tumor angiogenesis have clear effects
on tumor growth and metastasis through effects on their
blood vessels and blood supply.1–5 Increased VEGF levels in
tumor tissue or circulation have been found in most malig-
nancies and are often associated with metastasis formation
and poor prognosis. Thus, therapies targeting VEGF, a key
angiogenic factor, have become an important modality for the
treatment of cancer.5–7
Anti-VEGF agents currently in clinical practice and
development include antibodies to VEGF or VEGF receptor
(VEGFR)-blocking antibodies, soluble receptors, low-molec-
ular-weight VEGFR tyrosine kinase inhibitors (TKIs), anti-
sense oligonucleotides, and RNA interference agents. Bev-
acizumab (Avastin; Genentech, Inc., San Francisco, CA) is
the first antiangiogenic treatment approved by the American
Food and Drug Administration in the first-line treatment of
metastatic lung and colorectal cancer. Multitargeted VEGFR-
selective TKI vatanalib, sorafenib, and sunitinib have been
used in combinations with chemotherapeutic agents in phase
III clinical trials.5,8 These inhibitors have broader spectrum;
although they primarily target VEGFRs, their secondary
targets are other tyrosine kinase receptors including c-kit,
Flt3, and platelet-derived growth factor receptor-.
Combining anti-VEGF therapy with cytotoxic agents
has produced impressive results demonstrating the potential
benefits of targeting both endothelial and neoplastic cells in
colorectal, breast, and lung cancer.9–13 These survival bene-
fits come at a cost, however. Anti-VEGF therapies have rare
but serious associated toxicities, the cause of which is poorly
understood. Common toxicities associated with bevacizumab
include hypertension, proteinuria, bleeding episodes, throm-
botic events, and hematologic toxicity.14 In patients with
non-small cell lung cancer treated with chemotherapy, there
was a significant increase in the number of cases of neutro-
penia and pulmonary hemorrhage associated with the addi-
tion of bevacizumab. Increased hematologic toxicities were
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also reported for multitargeted VEGFR TKIs.5,8,15 Under-
standing the role of VEGF signaling in stress hematopoiesis
is essential for the development of therapeutic regimens and
establishment of optimal doses with limited risk of life-
threatening hematologic complications.
VEGF is known to have critical roles in the formation
and maintenance of blood vessels (angiogenesis, lym-
phangiogenesis, and vasculogenesis) and of blood cells (he-
matopoiesis). VEGF ligands exert their biologic effects
through different receptors, including VEGFR1 and
VEGFR2, which are expressed in endothelial cells and vari-
ous hematopoietic cell lineages in the adult.16 The current
body of evidence suggests that VEGFR2 mediates the ma-
jority of the downstream effects of VEGF-A on endothelial
cells and angiogenesis. VEGFR1 is involved in migration of
bone marrow-derived cells and is able to positively or nega-
tively influence VEGFR2 signaling.17–19 The VEGFR1/R2
heterodimer is present in some cell types and exerts a unique
function.20 Given the significant clinical benefits of the com-
bination, further studies will be needed to optimize the dosing
of chemotherapy in anti-VEGF combination regimens to
reduce the risk of severe hematologic toxicity.
MATERIALS AND METHODS
Reagents
DC101 and MF1 antibodies were generous gifts from
ImClone System Inc. (New York, NY). DC101 and MF1 are
rat-blocking monoclonal antibodies specific against mouse
VEGFR-2 and VEGFR-1, respectively. Control rat IgG was
purchased from Sigma-Aldrich (St. Louis, MO). Soluble
VEGFR1 fusion protein with the Fc portion of human IgG
(mFlt1(1-3)-IgG) was a gift from Genentech Inc. (San Fran-
cisco, CA).
All cytokines were from R&D Systems (Minneapolis,
MN), and culture medium and fetal bovine serum were from
GIBCO (Carlsbad, CA). 5-Fluorouracil (5-FU), adriamycin,
carboplatin, and dimethyl sulfoxide (DMSO) were purchased
from Sigma-Aldrich. SU5416 was purchased from Tocris
Biosciences (Ellisville, MO) and was solubilized in DMSO.
Final DMSO concentrations in assays in vitro did not exceed
0.1%, and the same DMSO concentrations were used in
vehicle controls.
Mice and In Vitro Experiments
All animal studies were conducted in accordance with
the Guide for the Care and Use of Laboratory Animals as
adopted and promulgated by the US National Institutes of
Health. Animal studies were reviewed and approved by the
Institutional Animal Care and Use Committee of the Vander-
bilt University.
C57BL/6 mice were purchased from The Jackson Lab-
oratory (Bar Harbor, ME). VEGFR1(TK/) mutant mice
lacking intracellular domain of VEGFR1 were obtained from
Dr. M. Shibuya (University of Tokyo)21 and back-crossed to
C57BL/6 genetic background for 10 generations. Seven- to
8-week-old, age- and sex-matched mice were used.
In myelosuppression experiments, mice received a
single injection of 300 mg/kg 5-FU and starting from the
same day were coinjected intraperitoneally with 6.5 mg/kg
SU5416 in 50 l DMSO or DMSO as a control at 2-day
intervals. SU5416 was used as a prototypic multitargeted
VEGFR TKI, which effectively blocks signal transduction
by VEGFR1 and VEGFR2, and by c-kit and FLT3.21 Blood
was collected from mice by retroorbital bleeding, and
white blood cell (WBC) counts and absolute neutrophil
counts were determined.
HPC Isolation
Mouse hematopoietic progenitor cells (HPCs) were
isolated from bone marrow of mice using immunomagnetic
negative selection with biotinylated antibodies against a panel
of lineage-specific antigens CD5, CD45R (B220), CD11b,
Gr-1, 7-4, and Ter-119 and antibiotin microbeads (Miltenyi
Biotec, Auburn, CA) according to the manufacturer’s proto-
col. The purity of lineage negative cells exceeded 95% by
flow cytometric analysis.
Flow Cytometry and Cell Cycle Analysis
Aliquots of bone marrow cells (105 cells in 100 l
buffer) were incubated with the respective fluorochrome-
conjugated monoclonal antibodies (ScaI-FITC, c-kit-PE
CD45-PerCP, Ter119-PE, CD11b-FITC, Gr-1, and CD45R-
PerCP all from BD Pharmingen, San Diego, CA) for 30
minutes on ice, washed, and analyzed using a FACSCalibur
flow cytometer (BD Immunocytometry Systems, Franklin
Lakes, NJ). Matched fluorochrome-conjugated IgG controls
were used in all experiments. Nonviable cells were excluded
using 7-amino actinomycin D.
Bone marrow lineage-negative HPC from 5-FU-in-
jected mice treated or not with SU5416 were fixed in ice-cold
ethanol. After RNase treatment (Sigma), cells were stained
with propidium iodide (Molecular-Probes, Eugene, Oregon).
DNA content of HPC was determined by flow cytometry.
In Vitro Proliferation of HPC
For the proliferation experiments, HPC were seeded in
96-well plates at a density of 5000 cells per well in DMEM
medium supplemented with 10% fetal bovine serum, colony-
stimulating factor (c-kit ligand, 50 ng/ml), interleukin-3 (5
ng/ml), and Flt3 ligand (FLT3L, 10 ng/ml) and cultured for 3
days. Chemotherapeutic drugs and anti-VEGF reagents were
added as indicated in figures at the beginning of cultures. Cell
proliferation was assessed after the addition of 1 Ci/well of
[3H]-thymidine (Amersham, Piscataway, NY) for the final 18
hours. All measurements were performed in triplicate and
presented as mean cpm  SE.
Statistical Analysis
Statistical analyses were performed using Excel soft-
ware. Differences between mean values were assessed using
Student t test. Values were considered statistically significant
when p values were less than 0.05.
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RESULTS
Multitargeted VEGFR-Selective TKI Impairs
WBC Recovery and Repopulation of the Bone
Marrow in Mice after Treatment with
Cytotoxic Chemotherapy
Using a mouse model, we examined the effect of a
VEGFR-multitargeted TKI on hematopoietic recovery after
myelosuppression using the prototype VEGFR-specific TKI
SU5416, which inhibits VEGFR1, VEGFR2, and VEGFR3.22,23
We also assessed the requirement for VEGFR1 tyrosine kinase
by comparing the reconstitution of bone marrow cells and WBC
in wild-type and animals bearing deletion of VEGFR1 tyrosine
kinase domain ([VEGFR1(TK/]).
A single injection of 5-FU in both types of mice led to
a rapid decline in WBC during the first 6 to 8 days followed
by a gradual reconstitution by day 16 to 18 in wild-type mice.
Animals lacking the tyrosine kinase domain of VEGFR1 had
the same levels of WBC at baseline and the same initial
decline in WBC counts after 5-FU injection as wild-type
mice. However, the reconstitution of WBC was significantly
impaired in mutant animals (Figure 1). Administration of
SU5416 at a dose that could effectively inhibit tumor angio-
genesis,24 but is not toxic under normal conditions, com-
pletely prevented WBC recovery in both types of mice
received 5-FU. In these groups, 80% of the mice succumbed
because of bone marrow failure.
The observed changes in WBC on combination treat-
ments corresponded to the alterations in bone marrow
cellularity as assessed on day 14 after 5-FU administration
(Figure 2). In both types of mice receiving 5-FU in
combination with SU5416, the total number of bone mar-
row mononuclear cells was about 3-fold less than in
untreated animals and was significantly lower than in
animals receiving 5-FU alone. Also, in VEGFR1(TK/)
mice, there were fewer cells than in wild-type controls on
day 14 after myelosuppression (Figure 2).
In VEGFR1(TK/) mutant animals, only VEGFR1
tyrosine kinase is dysfunctional, whereas the administration
of SU5416 inhibits all VEGFR. Collectively, these data
demonstrate that targeting VEGFR1 tyrosine kinase delays
but does not prevent bone marrow reconstitution, whereas a
multitargeted VEGFR TKI impairs hematopoietic recovery
after myelosuppression and may cause life-threatening pro-
longation of hematopoietic suppression.
Inhibition of VEGFR Signaling by a
Multitargeted TKI In Vivo Significantly
Attenuates Reconstitution of Hematopoietic
Precursors, Myeloid, and Erythroid Cellular
Subsets after Cytotoxic Chemotherapy
The analysis of cellular subsets within the bone marrow
of wild-type mice received cytotoxic treatment revealed that
the recovery of CD11b and CD11bGr1 myeloid cells
(Figure 3A), Sca-1c-kit hematopoietic precursors (Figure
3B), and Ter119CD45 erythroid cells (Figure 3C) was
affected by anti-VEGFR TKI therapy. We did not observe
significant effect of the VEGFR TKI on the recovery of B
lymphoid lineage (CD43CD45R cells, data not shown).
Combination Treatment of Mice by 5-FU and
SU5416 Slows Progression of Bone Marrow
HPC Through the Cell Cycle
We examined the cell cycle distribution of HPC iso-
lated from the bone marrow of wild-type mice treated with
5-FU with or without SU5416 on day 14 after 5-FU admin-
FIGURE 1. Genetic deletion of vascular endothelial growth
factor receptor 1 (VEGFR1) tyrosine kinase domain or admin-
istration of VEGF receptor-selective multitargeted TKI
SU5416 impair WBC recovery in mice after cytotoxic chemo-
therapy. WBC counts in wild-type (WT) or VEGFR1(TK/)
mice after a single dose of 300 mg/kg 5-fluorouracil (5-FU)
with or without treatment with 6.5 mg/kg SU5416 coin-
jected intraperitoneally at the same day and then every third
day. In both groups received 5-FU with SU5416, mortality
was 80% at day 14. Data are expressed as mean  SE.
FIGURE 2. Delayed repopulation of bone marrow in mice
with genetic deletion of vascular endothelial growth factor
receptor 1 (VEGFR1) tyrosine kinase domain or received
SU5416 treatment after cytotoxic chemotherapy. The num-
ber of cells in bone marrow (BM, tibia, and femurs) in wild-
type or VEGFR1(TK/) mutant mice on day 14 after receiv-
ing a single dose of 5-fluorouracil (5-FU) with or without
treatment with SU5416, as described in the legend for Fig-
ure 1. Data are expressed as mean  SE; *p  0.01; **p 
0.005.
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istration and found that inhibition of VEGFR signaling slows
the progression of HPC though the cell cycle significantly
decreasing the proportion of cells in S and G2/M phases
compared with 5-FU alone treatment (Table 1).
VEGF Signaling-Specific Agents and Anti-VEGF
Multitargeted TKI Decrease HPC Proliferation
and Add to the Toxicity of Cytotoxic Drugs
Various hematopoietic cell lineages including HPC
express VEGFRs. Bone marrow stem cells and HPC are also
dependent of SCF (c-kit ligand) and Flt3L signaling, which
are also less potently inhibited by this TKI. Thus, we assessed
the effect of VEGF-specific and multitargeted inhibitors on
the proliferation of bone marrow HPC in vitro to determine
the specific role of the VEGFRs in HPC proliferation and the
delayed bone marrow recovery observed after myelosuppres-
sive chemotherapy. Mouse bone marrow Lin HPC actively
proliferated in a medium containing supporting cytokines
including SCF and Flt3L (see Material and Methods section).
Addition of exogenous VEGF was not required for stimula-
tion of VEGF-dependent HPC proliferation, because HPC
themselves produce VEGF. In our proliferation experiments,
the concentration of endogenous VEGF reached 200  17.8
pg/ml (n  4) by the end of the assay (3 days). Blockade of
VEGF, c-kit, and Flt3 receptor tyrosine kinases by SU5416
effectively inhibited HPC proliferation in a dose-dependent
manner (Figure 4). HPC proliferation was also inhibited by a
combination of anti-VEGFR1- and anti-VEGFR2-blocking
antibodies interfering with the ligand binding and by the
removal of endogenously produced VEGF from the culture by a
soluble VEGFR1-Fc fusion protein (Figure 4). In some ex-
periments, SCF and Flt3L were omitted from the culture
medium to prevent HPC proliferation dependent on these
factors. In this case, SU5416 at a concentration of 100 nM
induced a 40.7  3.8% reduction of cell proliferation, which
was not statistically different from a 48.8  5.8% reduction
in the complete medium (n  6; p  0.12), thus indicating
that inhibition of HPC proliferation by SU5416 can occur
independently from its effect on c-kit and Flt3 activity.
We assessed the effect of treatment by various cyto-
toxic chemotherapeutic agents in combination with VEGFR
TKI on proliferation of HPC in vitro. When SU5416 was
added to 5-FU, carboplatin, or adriamycin, it decreased pro-
liferation of HPC to a greater degree compared with that
observed with the cytotoxic agents alone (Figure 5). Cyto-
toxic drugs and anti-VEGF TKI target different mechanisms
FIGURE 3. Inhibition of vascular endothelial growth factor
signaling in vivo significantly attenuates repopulation of my-
eloid, hematopoietic precursor, and erythroid cellular subsets
after cytotoxic chemotherapy. Mice were treated as de-
scribed in the legend for Figure 1, and proportions of cell
populations in bone marrow were assessed by flow cytom-
etry on day 14. A, CD11bGr1. B, ScaIc-kit cells. C,
Ter119CD45 cells. Data are expressed as mean  SE;
*p  0.01.
FIGURE 4. Inhibition of vascular endothelial growth factor
(VEGF) signaling by receptor TKI, antireceptor blocking anti-
bodies, or s vascular endothelial growth factor receptor 1
(VEGFR1)-Fc fusion protein decreases proliferation of mouse
Lin hematopoietic progenitor cell (HPC). Mouse Lin HPC
were cultured in the presence of supportive cytokines for 3
days without or with escalating doses of SU5416, mixture of
anti-VEGFR1-, and anti-VEGFR2-blocking antibodies or
sVEGFR1-Fc fusion protein. Cell proliferation was assessed
by [3H]-thymidine incorporation. Data are expressed as
mean  SE; *p  0.01; **p  0.005.
TABLE 1. Combination Treatment of Mice by 5-FU and
SU5416 Slows Progression of Bone Marrow HPC Through
the Cell Cycle
Treatment
Population (%)
G1/G0 S G2/M
Control 77.03  9.50 11.22  3.87 11.75  2.12
5-FU 74.43  7.35 11.04  2.83 14.52  3.85
5-FU  SU5416 86.58  5.88a 5.74  1.98a 7.68  2.08a
Mice were treated as indicated, and 14 d after 5-FU administration, bone marrow
cells were isolated, and progression of Lin cells through the cell cycle was assessed.
a P  0.05 compared 5-FU group.
5-FU, 5-fluorouracil.
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of cell growth, and we observed additive inhibitory effects
when they were used in combination.
DISCUSSION
The results of this study provide an explanation for the
earlier reported observations of the increased cases of neu-
tropenia in patients received a combination of chemotherapy
with anti-VEGF agents. Animal model studies reproduced the
prolonged leukopenia after combination chemotherapy and
provided additional details characterizing the effect of com-
bined cytotoxic and anti-VEGF treatment. Earlier, the essen-
tial role of VEGFR1-induced signaling in the hematopoietic
recovery was shown in animal models using blocking anti-
VEGFR antibodies.17,25 Our investigations using genetically
modified mice bearing deletion of tyrosine kinase domain of
VEGFR1 demonstrated the important role of the VEGFR1
tyrosine kinase, as in VEGFR1(TK/) mutant mice, the
reconstitution of the bone marrow was significantly slowed
compared with wild-type mice. Of importance is the fact that
VEGFR1(TK/) animals were able to readily recover after
myelosuppressive chemotherapy in contrast to mice receiving
anti-VEGFR1-blocking antibody along with a cytotoxic re-
agent.17 We view this as an additional indication that extra-
cellular and transmembrane domains of VEGR1 have certain
important physiologic functions in regulation of stress hema-
topoiesis separate from its kinase activity.
In our model system, the VEGFR multitargeted TKI
completely prevented hematopoietic recovery after chemo-
therapy and caused fatal bone marrow failure in a significant
proportion of the mice. This observation correlates with the
results of recent clinical trials of vatalanib, a multitargeted
anti-VEGF TKI, in combination with chemotherapy for colo-
rectal cancer patients that reported a high incidence of grades
3 and 4 neutropenia.5,8 Our studies also showed that inhibi-
tion of VEGFR signaling by VEGFR TKI primarily affected
the populations of HPC, myeloid, and erythroid cells in the
bone marrow. They suggest that a significantly slowed pro-
gression of bone marrow lineage-negative HPC through the
cell cycle is the underlying mechanism behind the delayed
hematopoietic recovery after combination therapy.
In vitro data demonstrated that blockade of VEGFR
signaling at any level, including removal of the ligand,
abrogation of the receptor-ligand interaction, or receptor
tyrosine kinase signaling, could effectively inhibit HPC pro-
liferation. Together with the published clinical and experi-
mental data, our in vivo and in vitro data are consistent with
the conclusion that interference with VEGF signaling by any
type of anti-VEGF agent could cause delayed hematopoietic
recovery and increases the risk of neutropenia or other he-
matologic complications when used in combination with
chemotherapy. The addition of a multitargeted VEGFR TKI
to chemotherapy will likely have the highest risk of hemato-
logic toxicities, if they target other tyrosine kinase receptors
important for survival and proliferation of HPC, such as c-kit
and Flt3. Previously, it was reported that overexpression of
c-kit ligand in mice receiving cytotoxic chemotherapy with
anti-VEGFR1-blocking antibody could abrogate myelosup-
pression, and c-kit ligand was proposed as a possible myelo-
supportive therapy.17 This ligand and Flt3L would likely only
be effective when used with anti-VEGF or anti-VEGFR
antibodies but not a multitargeted TKI like SU5416.
Earlier investigations suggested the existence of an
internal autocrine loop formed by VEGF and its receptors
based on the fact of inhibition of HPC proliferation by small
molecule cell-permeable TKI but not by anti-VEGF or block-
ing anti-VEGFR antibodies.26 However, in our in vitro ex-
periments, we found that all types of reagents disrupting
VEGF signal transduction effectively inhibited HPC prolif-
eration. Differences between in vivo effects reported for
anti-VEGFR antibodies17 and our data on VEGFR1(TK/)
mice and SU5416 treatment of animals after myelosuppres-
sion could potentially be attributed to as yet unknown mech-
anisms of VEGFR signaling associated with the internal
autocrine loop or heterodimerization.
In summary, our study revealed that anti-VEGF treat-
ment in combination with chemotherapy could significantly
delay leukocyte recovery through the inhibition of VEGFR1-
and VEGFR2-dependent bone marrow HPC proliferation.
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FIGURE 5. Combination of multitargeted vascular endothelial
growth factor (VEGF) receptor TKI SU5416 with chemothera-
peutic reagents has additive inhibitory effect on hematopoietic
progenitor cell (HPC) proliferation. Mouse Lin HPC were
cultured without or with 100 nM SU5416, 20 nM 5-fluorou-
racil (5-FU), 1.5 g/ml carboplatin (CP), 5 ng/ml adriamicyn
or combination of SU5416, and chemotherapeutic agents
at the same concentrations. Cell proliferation was assessed
by [3H]-thymidine incorporation. Data are expressed as
mean  SE; *p  0.01; **p  0.005.
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